🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Marc Ditmarsch

ORCID: 0000-0002-2970-1893

MedicineBiochemistry, Genetics and Molecular BiologyEconomics, Econometrics and Finance

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 3 papers. Top paper: “Rationale and design of the REMBRANDT trial: A phase 3 study to evaluate the effect of obicetrapib/ezetimibe on coronary plaque characteristics”.

Rationale and design of the REMBRANDT trial: A phase 3 study to evaluate the effect of obicetrapib/ezetimibe on coronary plaque characteristics

American Heart Journal(2025)10.1016/j.ahj.2025.07.012

N/A

0.522DataRank · unranked

9 citations

Christie M. Ballantyne, Ron Blankstein, Matthew J Budoff, Marc Ditmarsch, C. Michael Gibson +8 more

CETP and SGLT2 inhibitor combination therapy improves glycemic control

medRxiv(2023)10.1101/2023.06.13.23291357

N/A

0DataRank · unranked

0 citations

Patrick Sun, Marc Ditmarsch, John J.P. Kastelein, Michael H. Davidson, Bohdan B. Khomtchouk

CETP and SGLT2 inhibitor combination therapy increases glycemic control: a 2x2 factorial Mendelian randomization analysis

Frontiers in Endocrinology(2024)10.3389/fendo.2024.1359780

N/A

0DataRank · unranked

1 citations

Patrick Sun, Zane A. Maggio, Marc Ditmarsch, John J.P. Kastelein, Michael H. Davidson +1 more